CYTH4

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CYTH4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CYTH4 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYTH4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYTH4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and GBM are the cancer types where CYTH4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCOSMedianAll1.0000.449.03318view →
LSCCOSQuartileIII,IV0.9700.659.0246view →
GBMOSMedianAll0.4350.618.0244view →
PDACOSMedianII,III,IV0.7010.942.0124view →
LUADDFSMedianAll0.7340.525.0234view →
CCRCCOSQuartileIII,IV0.6111.000.0271view →
Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CYTH4–HNSC (OS)

Kaplan–Meier survival curve for CYTH4 mass-spec protein-high vs -low samples in HNSC.

Open the HNSC breakdown →

Exploration